Gladstone Investment Corporation - 5.00% Notes Due 2026 Stock (NASDAQ: GAINN)

Gladstone Investment Corporation - 5.00% Notes Due 2026 Stock (NASDAQ:GAINN), Trade Ideas

Gladstone Investment Corporation - 5.00% Notes Due 2026

Telesat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSAT#NASDAQ">TSAT</a>) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $0.04 by 2102.5 percent. This is a 282.05 percent decrease over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $112.900 million which missed the analyst consensus estimate of $113.850 million by 0.83 percent. This is a 16.79 percent decrease over sales of $135.680 million the same period last year.

Earnings

Earnings Misses

News

TSAT

CORRECTION: Telesat Q1 2024 GAAP EPS $(0.80) Misses $0.04 Estimate, Sales $112.900M Miss $113.850M Estimate

IPSC

Century Therapeutics Presents Preclinical Data Highlighting Advances In iPSC Platform Technology And Programs At 2024 ASGCT Annual Meeting

Baird analyst Catherine Ramsey maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Outperform and raises the price target from $99 to $117.

Price Target

Analyst Ratings

NTRA

Baird Maintains Outperform on Natera, Raises Price Target to $117

Baird analyst Eric Coldwell maintains Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with a Outperform and lowers the price target from $282 to $270.

Baird Maintains Outperform on Charles River, Lowers Price Target to $270

The Dow Jones index closed higher by over 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">ESS Tech</h3>
<ul>
<li>The Trade: ESS Tech, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) Director Harry Quarls <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 42,690 shares</a> at an average price of $0.84. To acquire these shares, it cost around $35,817.</li>
<li>What's Happening: On May 7, ESS Tech posted a narrower-than-expected quarterly loss.</li>
<li>What ESS Tech Does: ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology.</li>
</ul>
<h3 class="wp-block-heading">Cerus</h3>
<ul>
<li>The Trade: Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) Director Daniel N Swisher Jr <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 2,500 shares at </a>an average price of $1.88. To acquire these shares, it cost around $4,689.</li>
<li>What's Happening: On May 2, Cerus said product revenue during the first quarter of 2024 was $38.4 million, up from $31.0 million in the year-ago period.</li>
<li>What Cerus Does: Cerus Corp is a biomedical products company focused on the field of blood transfusion safety.</li>
</ul>
<h3 class="wp-block-heading">Sabre</h3>
<ul>
<li>The Trade: Sabre Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABR#NASDAQ">SABR</a>) CEO and President Kurt Joseph Ekert <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 65,000 shares</a> at an average price of $2.57. The insider spent around $167,050 to buy those shares. The company's EVP and Chief Legal Officer also bought 20,000 shares.</li>
<li>What's Happening: On May 2, Sabre reported better-than-expected first-quarter results and updated FY24 revenue outlook.</li>
<li>What Sabre Does: Sabre holds the number-two air booking volume share in the global distribution system industry.</li>
</ul>
Read More: Enbridge, <a href="https://www.benzinga.com/news/earnings/24/05/38753455/enbridge-funko-and-3-stocks-to-watch-heading-into-friday">Funko And 3 Stocks To Watch Heading Into Friday</a>

Long Ideas

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

CERS

SABR

ESS Tech And 2 Other Stocks Under $5 Insiders Are Buying

Arcadium Lithium plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTM#NYSE">ALTM</a>) (ASX: LTM), &quot;Arcadium Lithium&quot; or &quot;the Company&quot;) today announced that it has applied to the Autorit&eacute; des march&eacute;s financiers, as principal regulator, and the Ontario Securities Commission, (collectively, the &quot;Canadian Securities Regulatory Authorities&quot;) for an order (the &quot;Order Sought&quot;) to cease to be a reporting issuer in&nbsp;British Columbia,&nbsp;Alberta,&nbsp;Saskatchewan,&nbsp;Manitoba,&nbsp;Ontario, Qu&eacute;bec,&nbsp;New Brunswick,&nbsp;Nova Scotia,&nbsp;Prince Edward Island&nbsp;and&nbsp;Newfoundland&nbsp;and&nbsp;Labrador, Canada&nbsp;(collectively, the &quot;Jurisdictions&quot;). &nbsp;

ALTM

Arcadium Lithium Makes Application To Cease To Be A Reporting Issuer In Canada

The Q1 earnings report for NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) was released on Tuesday, April 30, 2024 at 07:30 AM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
NeoGenomics beat estimated earnings by 60.0%, reporting an EPS of $-0.02 versus an estimate of $-0.05.
Revenue was up $19.02 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
Last quarter the company beat on EPS by $0.05 which was followed by a 12.0% increase in the share price the next day.
Here's a look at NeoGenomics's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.05</td>
<td>-0.02</td>
<td>-0.08</td>
<td>-0.11</td>
<td>-0.15</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.02</td>
<td>0.03</td>
<td>0</td>
<td>-0.05</td>
<td>-0.09</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>149.89M</td>
<td>152.54M</td>
<td>142.00M</td>
<td>137.42M</td>
<td>126.39M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>156.24M</td>
<td>155.55M</td>
<td>151.95M</td>
<td>146.92M</td>
<td>137.22M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
NeoGenomics management provided guidance for FY 2024, expecting earnings between $0.0 and $0.04 per share.
<h3>Recent Earnings Releases from Competitors</h3>
With NeoGenomics's earnings data in hand, it's essential to compare its metrics to those of similar companies, including BrightSpring Health, Guardant Health, and R1 RCM.
<ul>
<li>BrightSpring Health's earnings on May 02, 2024 exceeded market projections, revealing an EPS of $0.12 compared to the estimated EPS of $0.07, resulting in a 71.43% increase.</li>
<li>The latest earnings announcement from Guardant Health on May 09, 2024 exceeded expectations, with an actual EPS of $-0.46 compared to the market's estimate of $-0.85, resulting in a 45.88% increase.</li>
<li>On May 08, 2024, R1 RCM unveiled earnings that were below market expectations, with an actual EPS of $-0.08 compared to an estimated EPS of $-0.01, resulting in a -700.0% decrease.</li>
</ul>
<h3>Competitors Quarterly Earnings and Stock Performance Analysis</h3>
This analysis provides insights into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with the corresponding stock prices at the close of the announcement day and the open of the following trading day.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Date</th>
<th style="text-align: right;">EPS Expected</th>
<th style="text-align: right;">EPS Announced</th>
<th>EPS Change Percent</th>
<th>Stock Price At Close</th>
<th>Stock Price at Next Day Open</th>
<th>Price Change Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>NeoGenomics</td>
<td>April 30, 2024</td>
<td style="text-align: right;">-0.05</td>
<td style="text-align: right;">-0.02</td>
<td>60.0%</td>
<td>$13.92</td>
<td>$14.0</td>
<td>0.57%</td>
</tr>
<tr>
<td>BrightSpring Health</td>
<td>May 02, 2024</td>
<td style="text-align: right;">0.07</td>
<td style="text-align: right;">0.12</td>
<td>71.43%</td>
<td>$11.06</td>
<td>$11.27</td>
<td>1.9%</td>
</tr>
<tr>
<td>Guardant Health</td>
<td>May 09, 2024</td>
<td style="text-align: right;">-0.85</td>
<td style="text-align: right;">-0.46</td>
<td>45.88%</td>
<td>$19.44</td>
<td>$21.84</td>
<td>12.35%</td>
</tr>
<tr>
<td>R1 RCM</td>
<td>May 08, 2024</td>
<td style="text-align: right;">-0.01</td>
<td style="text-align: right;">-0.08</td>
<td>-700.0%</td>
<td>$12.84</td>
<td>$12.67</td>
<td>-1.32%</td>
</tr>
</tbody>
</table>

<h3>Analyzing Peer Revenue Discrepancy: Estimated vs. Announced</h3>
The comparison table below presents estimated and announced revenue figures for NeoGenomics's peers. This comparison provides insights into the revenue performance of these companies, offering valuable context for understanding their financial standing within the industry.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Estimated Revenue</th>
<th>Announced Revenue</th>
<th>Revenue Surprise Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>NeoGenomics</td>
<td>149.89M</td>
<td>156.24M</td>
<td>4.24%</td>
</tr>
<tr>
<td>BrightSpring Health</td>
<td>2.31B</td>
<td>2.58B</td>
<td>11.56%</td>
</tr>
<tr>
<td>Guardant Health</td>
<td>150.67M</td>
<td>168.49M</td>
<td>11.83%</td>
</tr>
<tr>
<td>R1 RCM</td>
<td>611.93M</td>
<td>603.90M</td>
<td>-1.31%</td>
</tr>
</tbody>
</table>

To track all earnings releases for NeoGenomics <a href="https://www.benzinga.com/quote/NEO/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NeoGenomics Earnings Analysis: Q1 Recap

WIIM

Gen Digital shares are trading higher after the company reported better-than-expected Q4 earnings and authorized a $3 billion share repurchase program.

Ritchie Bros Auctioneers shares are trading higher after the company reported better-than-expected Q1 financial results.

Baird analyst Timothy Wojs maintains Trex Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) with a Neutral and lowers the price target from $110 to $105.

TREX

Baird Maintains Neutral on Trex Co, Lowers Price Target to $105

AngloGold Ashanti shares are trading higher after the company reported Q1 gold production.

Baird analyst Mark Altschwager maintains Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) with a Outperform and lowers the price target from $52 to $50.

Baird Maintains Outperform on Tapestry, Lowers Price Target to $50

Taiwan Semiconductor shares are trading higher after the company reported an increase in April revenue.

ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.25) by 36 percent. This is unchanged from the same period last year.

Earnings Beats

PROK

ProKidney Q1 EPS $(0.16) Remains Flat YoY, Exits Quarter With Cash & Equivalents Worth $329M

Baird analyst Mark Altschwager maintains Savers Value Village (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVV#NYSE">SVV</a>) with a Outperform and lowers the price target from $23 to $21.

Baird Maintains Outperform on Savers Value Village, Lowers Price Target to $21

CRH shares are trading higher after the company reported Q1 earnings.

Needham analyst Quinn Bolton maintains Synaptics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYNA#NASDAQ">SYNA</a>) with a Buy and lowers the price target from $125 to $110.

SYNA

Needham Maintains Buy on Synaptics, Lowers Price Target to $110

DOCN

DigitalOcean Holdings shares are trading higher following better-than-expected Q1 earnings and upbeat guidance.

U.S. stocks are on track to finish the week on a high, with the index futures pointing to a higher opening on Friday. The <a href="https://www.benzinga.com/markets/equities/24/05/38734795/unemployment-claims-surge-more-than-expected-hit-8-month-peak-dollar-falls-as-traders-bet-on-rat">recent string of weak data </a>has given raise to hopes that the Federal Reserve may have to relent and take rates lower. A few Federal Reserve speeches scheduled for the day will likely offer some color on what the central bank may do with rates this year.
A consumer sentiment reading and inflation expectations, which are a part of the report, and tapering earnings news flow could also impact trader sentiment. All eyes will be on the S&amp;P 500 Index to see if the upward momentum is strong enough to lift it past late March closing highs of 5,248.49.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>+0.48%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>+0.38%</td>
</tr>
<tr>
<td>Dow</td>
<td>+0.33%</td>
</tr>
<tr>
<td>R2K</td>
<td>+0.36%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption"> In <a href="https://www.benzinga.com/premarket/" target="_blank" rel="noreferrer noopener">premarket</a>&nbsp;trading on Friday, the&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.37% to $522.10,&nbsp;while the&nbsp;Invesco QQQ ETF&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) gained 0.46% to $443.03, according to&nbsp;<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.</figcaption></figure>
Cues From Previous Session:
Thanks to a spike in jobless claims to the highest since August 2023, the major averages all ended firmly in the green on Thursday. Commenting on the data, fund manager Louis Navellier said, &#8220;Overall, since the Fed has an unemployment mandate, rising jobless claims should help to coax the Fed to cut key interest rates sooner than later.&#8221;
The indices opened on a mixed note, but turned uniformly higher in late-morning trading. Subsequently, they stayed firmly in the green before ending the session higher. All S&amp;P sectors, with the exception of IT stocks, gained ground, with energy and real estate stocks seeing standout gains.
The Dow Jones Industrial Average extended its winning streak to seven, with the Dow, S&amp;P 500 Index and the Russell 2,000 Index now at their highest closing levels in over a month. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td> Index</td>
<td> Performance (+/-)</td>
<td> Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>+0.27%</td>
<td>16,346.26</td>
</tr>
<tr>
<td>S&amp;P 500 Index</td>
<td>+0.51%</td>
<td>5,214.08</td>
</tr>
<tr>
<td>Dow Industrials</td>
<td>+0.85%</td>
<td>39,387.76</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>+0.90%</td>
<td>2,073.63</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Fund Strat&#8217;s Tom Lee sees the week&#8217;s market performance as positive. While noting that the S&amp;P 500 Index was up 1.7% so far this week on a &#8220;light macro&#8221; week, the market strategist said, &#8220;It's positive that markets drift higher on the absence of data.&#8221;
He also remarked about the outsized gains by small-cap stocks. The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) has added 1.96% this week.
Fund Strat sees the upcoming April inflation data coming in line and highlighting the possibility that &#8220;auto insurance's disproportionate impact on CPI is ebbing.&#8221; The firm expects this to push higher the number of Fed cuts for the year, which is positive for stocks. &#8220;Bottom line, we are still &#8216;buy in May.&#8217; The fact that stocks rose this week is a positive signal,&#8221; it said.
Upcoming Economic Data:
<ul>
<li>Fed Governor Michelle Bowman is scheduled to speak at 9 a.m. EDT.</li>
<li>The University of Michigan will release its preliminary consumer sentiment index for May at 10 a.m. EDT. Economists expect the index to come in at 76, down from 77.2 in April. The report also has a few inflation expectations readings, which will likely clarify about the forward inflation outlook.</li>
<li>Chicago Fed President Austan Goolsbee and Minneapolis Fed President Neel Kashkari are due to speak at 1 p.m. EDT.</li>
<li>Fed Vice Chair for Supervision Michael Barr will make a public appearance at 1:30 p.m. EDT.</li>
<li>The U.S. Treasury will release its monthly federal budget for April at 2 p.m. EDT, with the balance expected to turn to a surplus of $244.5 billion from a deficit of $235 billion in March.</li>
</ul>
See also: <a href="https://www.benzinga.com/money/best-futures-trading-software">Best Futures Trading Software</a>
Stocks In Focus:
<ul>
<li> Akamai Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>) fell over 10% <a href="https://www.benzinga.com/premarket">in premarket trading</a> following the company&#8217;s quarterly results announcement.</li>
<li>Other stocks moving on earnings are Blink Charging Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) (over 3.50%), Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) (down about 10.5%), Natera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) (up over 15%) and Yelp Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YELP#NYSE">YELP</a>) (down over 7%).</li>
<li>Victoria&#8217;s Secret &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) climbed over 6% following the release of its preliminary first-quarter results.</li>
<li>Enbridge Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>) and Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) are among the <a href="https://www.benzinga.com/calendars/earnings">notable companies due to release their quarterly results ahead of the market opening.</a></li>
</ul>
Commodities, Bonds, and Global Equity Markets:
Crude oil futures rose for a third straight session and they were up about 0.72% to a little under $80 a barrel. Meanwhile, gold futures rallied over 1.75% to $2,382.15. The 10-year bond yield, which pulled back on Thursday in the wake of the jobless claims data, traded up 2 basis points to 4.451%.
The Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose over 3% and has topped $35,000.
The global equity markets were all in the green on Friday, tracking the buoyancy on Wall Street overnight. Asian stocks closed higher, led by the Hong Kong market, although the Malaysian markets ended marginally lower. The major European markets advanced in early trading, with the Euro STOXX 50 Index up 0.80%.
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38746512/utilities-notch-7th-straight-session-of-gains-potential-derivative-play-to-the-ai-b">Utilities Notch 7th Straight Session Of Gains: &#8216;Potential Derivative Play To The AI Boom&#8217;</a>
Photo by Jirapong Manustrong on Shutterstock

Equities

Futures

Previews

Economics

Federal Reserve

Movers

$BTC

AKAM

BLNK

NTNX

NVAX

NVTS

VSCO

YELP

US Stocks Set To End Week Strong With S&P 500 Eyeing Break Above Late-March Peak: Analyst Says He's Still A Buy In May Amid This Positive Signal

Calumet Specialty Prods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.57) by 10.53 percent. This is a 321.74 percent decrease over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $1.005 billion which beat the analyst consensus estimate of $900.795 million by 11.57 percent. This is a 3.09 percent decrease over sales of $1.037 billion the same period last year.

CLMT

Calumet Specialty Prods Q1 2024 GAAP EPS $(0.51) Beats $(0.57) Estimate, Sales $1.005B Beat $900.795M Estimate

Gladstone Investment (GAIN) Q2 2024 Earnings Call Transcript

Ares Capital's NAV, Valuation, And Dividend Vs. 14 BDC Peers - Part 1 (Includes Recommendations As Of 12/8/2023)

Ares Capital's NAV, Valuation, And Dividend Vs. 14 BDC Peers - Part 2 (Includes Q1 + Q2 2024 Dividend Projection)

Gladstone Investment: A Strong Monthly Payer But Looking A Bit Rich

Saratoga Investment (Down Big): 40+ Big-Yield BDCs Compared

Gladstone Investment (GAIN) Q3 2024 Earnings Call Transcript

Ares Capital's NAV, Valuation, And Dividend Versus 14 BDC Peers - Part 1 (Includes Recommendations As Of 3/8/2024)

Ares Capital's NAV, Valuation, And Dividend Vs. 14 BDC Peers - Part 1 (Includes Recommendations As Of 3/8/2024)

Ares Capital's NAV, Valuation, And Dividend Versus 14 BDC Peers - Part 2 (Includes Q2 + Q3 2024 Dividend Projection)